Iterum Therapeutics Plc

0.00 (+1.09%)
Regulatory, Earnings Announcements

Iterum Therapeutics Reports Q3 Net Income Of $3.7 Mln

Published: 11/12/2021 12:30 GMT
Iterum Therapeutics Plc (ITRM) - Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update.
Iterum Therapeutics Plc - Cash Runway Into 2024.
Iterum Therapeutics Plc - Type B Meeting With FDA Requested to Affirm Design for Additional Phase 3 Trial Needed for Resubmission of NDA for Oral Sulopenem.
Iterum Therapeutics Plc - for Q3 of 2021, Iterum Reported Net Income of $3.7 Million.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.04

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.04

More details on our Analysts Page.